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DOI 10.1016/j.immuni.2009.09.007Immunotherapy, especially therapeutic
vaccination, has a great deal of potential
in the treatment of cancer and certain
infectious diseases such as HIV (Allison
et al., 2006; Fauci et al., 2008; Feldmann
and Steinman, 2005). Numerous vaccine
candidates have been tested in patients
with a variety of tumor types and chronic
viral diseases. Often, the best way to
assess the clinical potential of these
vaccines is to monitor the induced T cell
response, and yet there are currently no
standards for reporting these results. This
letter is an effort to address this problem.
In particular, various T cell assays have
been developed to try to predict vaccina-
tion success or failure and to ultimately
serve as biomarkers and subsequent clin-
ical endpoints in immunotherapy trials
(Hoos et al., 2007). Over the years, a few
assays have emerged that have been
widely used, such as ELISPOT, peptide-
MHC multimer, and intracellular cytokine
staining (ICS). Yet, these ‘‘classical’’
assays continue to be modified on
a regular basis as additional parameters
and innovations in technology are intro-
duced (Chattopadhyay et al., 2008).
Further, an increasing number of innova-
tive therapies and compounds are moving
into clinical trials, and novel monitoring
techniques are evolving in step. Because
each new modification has the potential
to substantially change the performance
characteristics of a test, results obtained
by different centers with slightly modified
assays are likely to vary in ways that are
impossible to predict. This compounds
the variations in assay results from facilityto facility, as revealed by the outcome of
recent multi-institutional studies for
ELISPOT, peptide-MHC multimer, and
ICS assays (Figure S1 available online).
The high degree in variability makes the
comparison between any two labs
becomes a game of chance. Additional
factors that can dramatically impact the
performance characteristics of assay
protocols are related to the analysis, inter-
pretation, and reporting of data and the
extent of quality measures taken to
ensure data integrity. To date, no formal
quality-control standards exist for labora-
tories performing such studies, nor does
any requirement for reporting on such
controls. This is in contrast to other, non-
immunological types of assays, such as
gene expression arrays.
The importance and influence of these
parameters is currently being evaluated
through large ongoing collective initiatives
with the goal to enhance bioassay stan-
dardization, validation, and harmonization
(Britten et al., 2008). Dedicated confer-
ences and formal sessions at large
international meetings underline the
increasing focus on immune-monitoring
techniques and will help to establish these
assays as reliable tools to systematically
dissect immune responses in humans
and create a reliable foundation for immu-
notherapy (Davis, 2008).
An area that remains unaddressed by
currently published recommendations
and guidelines relates to the establish-
ment of a reporting framework for
immune-monitoring assays. It is clear
from the discussion above that theImmunity 3absence of specific information on both
the assay procedure as well as the quality
infrastructure of individual laboratories
makes it difficult to interpret results objec-
tively. In only a painfully small number of
current publications do the authors provide
sufficient transparency on these points.
Hence, it is not surprising that results are
often regarded with skepticism.
In this letter, we introduce the project on
‘‘Minimal Information about T Cell Assays’’
(MIATA) with recommendations on the
minimum specific information required for
a more objective assessment of both the
quality of the laboratory infrastructure and
the assays themselves, to allow a thorough
interpretation of results from immunolog-
ical T cell assays. With this project’s intro-
duction, we invite the scientific community
to participate in a public consultation
phase. A comprehensive draft document
is posted and accessible online (www.
miataproject.org). Feedback will be col-
lected and incorporated during the year-
long public consultation period and
formally discussed in various meetings in
order to reach a consensus document on
what the reporting requirements should
be. With the assumption that a broad
consensus can be reached, these guide-
lines will becomethe framework for a public
database of immune-monitoring data
generated in the relevant clinical trials.
We wish to emphasize that MIATA is not
intended to impose any particular assays
or assay standards because this would
be an obstacle to innovation and improve-
ment of immune-monitoring technologies.
What we wish to define is the content1, October 16, 2009 ª2009 Elsevier Inc. 527
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from immunoassays. Although reporting
frameworks will not per se decrease the
interlaboratory variability found across
institutions, they will introduce more trans-
parency to published data and will allow
a reader to judge the quality of reported
results, a scenario that will improve the
ability to interpret immune-monitoring
results and aid in their adoption.
The current lack of a frameset for
reporting data from T cell assays should
also be seen in the context of an
increasing number of minimal information
projects that have emerged during the last
years. Many of these are listed under the
project on Minimum Information for Bio-
logical and Biomedical Investigations
(MIBBI) (Taylor et al., 2008). The presently
developed guidelines aim for two major
goals: first, to annotate data to such an
extent that they give transparent evidence
on the quality, reliability, and possible
error sources of reported results; and
second, to use the reporting standards
to supply public databases with more
interpretable results (Brazma et al., 2000).
Although some published guidelines
touch upon certain aspects of the MIATA
project, they do not fully address the unique
features and peculiarities of T cell-based
immunoassays, and no public database
for clinical immune-monitoring data yet
exists.
The initial MIATA guideline draft is
based on data and reports previously
published and focuses solely on those
variables that have been shown to influ-
ence the outcome of the three most
commonly used T cell-based immunoas-
says: ELISPOT, ICS, and peptide-MHC
multimer staining.
The proposed initial publication guide-
lines of immune-monitoring strategies
are based on the premise that reports of
immune-monitoring data generated by
the mentioned assays should accurately
include information on and description of
five important components that deter-
mine the testing outcome:
1. The sample, including information
about the donor or patient (such
as age, gender, human leukocyte
antigen (HLA) type, disease, treat-
ment, and comedication as far as
appropriate), techniques used for
obtaining, processing, freezing,
transporting, and storing the spec-528 Immunity 31, October 16, 2009 ª2009 Eimen tested, as well as the way
frozen samples were thawed and
quality tested before use in the
assay;
2. The assay, including crucial assay
techniques, reagents, materials,
and equipment assuring transpar-
ency of all assay conditions and, if
applicable, a statement of how
publicly available assay recom-
mendations were followed;
3. The data acquisition, including the
machines and software used for
data acquisition, their setup and cali-
bration, as well as the strategy to
analyze the specific events or spots;
4. The results, including statistical
or empirical response criteria,
comments on the considered bio-
logical significance of the obtained
results, and comments on whether
the results found can be correlated
with a specific disease stage or
treatment;
5. The environment in which laboratory
operations are conducted, including
the status of the use of standard
operating procedures (SOPs), qual-
ification and/or validation, compli-
ance with good laboratory practice
(GLP), training status of personnel
performing tests, quality-control
mechanisms, and responsibilities,
as well as auditing processes and
reporting of unexpected events.
Detailed annotation of published data
for these five modules should be accom-
panied by the reporting of raw data when-
ever this is needed to guarantee full
understanding of the value of the data set.
A transparent description of procedures
and quality measures applied during
immune monitoring is an important step
toward achieving proper scientific recogni-
tion of reported data, whether done in
a basic research setting or during clinical
vaccine testing. Furthermore, the reporting
of minimal information about immunomo-
nitoring assays will provide an important
tool for achieving comparability of results
across laboratories and institutions.
All of our colleagues are invited to
actively contribute to the draft guidelines
during the public consultation process.
We are aiming at an intensive vetting pro-
cess that is expected to lead to substantial
changes and a stepwise increase of
quality. To reach this goal, we will activelylsevier Inc.promote the guidelines and involve organi-
zations and groups as well as other leaders
in the immune-monitoring field, editors of
scientific journals, and representatives of
regulatory agencies in a process aiming
at reaching a broad consensus for next
versions of the guidelines.
The final goal of our project is to estab-
lish a well-vetted and commonly accept-
able reporting standard for immunomoni-
toring results that could be used to
systematically fill an openly accessible
public database. Such a searchable pub-
lic repository would be elemental for the
scientific community and drug developers
because results could be subjected to
comparative analyses within the context
of additional findings reported by col-
leagues working in a similar setting.
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